[go: up one dir, main page]

PT2356090T - Formas cristalinas de fingolimod, hcl - Google Patents

Formas cristalinas de fingolimod, hcl

Info

Publication number
PT2356090T
PT2356090T PT97483507T PT09748350T PT2356090T PT 2356090 T PT2356090 T PT 2356090T PT 97483507 T PT97483507 T PT 97483507T PT 09748350 T PT09748350 T PT 09748350T PT 2356090 T PT2356090 T PT 2356090T
Authority
PT
Portugal
Prior art keywords
crystalline forms
fingolimod hcl
fingolimod
hcl
crystalline
Prior art date
Application number
PT97483507T
Other languages
English (en)
Inventor
Mutz Michael
Jordine Guido
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2356090T publication Critical patent/PT2356090T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT97483507T 2008-11-11 2009-11-10 Formas cristalinas de fingolimod, hcl PT2356090T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168865 2008-11-11

Publications (1)

Publication Number Publication Date
PT2356090T true PT2356090T (pt) 2017-10-16

Family

ID=40521487

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97483507T PT2356090T (pt) 2008-11-11 2009-11-10 Formas cristalinas de fingolimod, hcl

Country Status (14)

Country Link
US (2) US8530522B2 (pt)
EP (1) EP2356090B1 (pt)
JP (4) JP2012508216A (pt)
KR (2) KR101393994B1 (pt)
CN (3) CN102209705A (pt)
AU (1) AU2009315736B2 (pt)
BR (1) BRPI0921826A2 (pt)
CA (1) CA2743232C (pt)
ES (1) ES2643161T3 (pt)
MX (1) MX2011004962A (pt)
PL (1) PL2356090T3 (pt)
PT (1) PT2356090T (pt)
RU (2) RU2015111229A (pt)
WO (1) WO2010055028A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621889B1 (en) 2010-10-01 2019-07-17 Synthon BV Process for making fingolimod hydrochloride crystals
EP2632889B1 (en) 2010-10-28 2018-08-29 Mapi Pharma Limited Intermediate compounds and process for the preparation of fingolimod
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2646409A4 (en) * 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMODE POLYMORPHS AND METHODS THEREOF
ES2746016T3 (es) 2010-12-28 2020-03-04 Synthon Bv Procedimiento para la preparación de cristales de clorhidrato de fingolimod
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
EP2702034A4 (en) 2011-04-29 2015-03-25 Reddys Lab Ltd Dr PREPARATION OF FINGOLIMOD AND ITS SALTS
DK2809648T3 (da) 2011-05-26 2019-06-17 Gri Bio Inc Oxygenberigede amino- eller ammonium-holdige sulfonsyrederivater og disses medicinske anvendelse
CA2887385C (en) 2011-05-26 2017-01-10 Glycoregimmune, Inc. Carrying On Business As Gri Bio, Inc. Hydroxy-substituted amino and ammonium derivatives and their medical use
DK2809318T3 (da) * 2011-05-26 2019-07-22 Gri Bio Inc Ammoniumholdige sulfonsyre-, phosphonsyre- og carboxylsyrederivater og disses medicinske anvendelse
US9186333B2 (en) 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
WO2013091704A1 (en) * 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
EP2945927A4 (en) * 2013-01-17 2017-01-18 Shilpa Medicare Limited Process for preparation of fingolimod and its salts
CA2903708C (en) 2013-03-05 2021-07-13 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
JP6316422B2 (ja) * 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
CN106667981B (zh) * 2017-01-16 2019-05-14 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗药物性肝损伤药物中的应用
CN106860440A (zh) * 2017-01-16 2017-06-20 南京医科大学第二附属医院 盐酸芬戈莫德在制备治疗系统性红斑狼疮脑病药物中的应用
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2020245775A1 (en) * 2019-06-05 2020-12-10 Biocon Limited Crystalline forms of 2-amino-2-(2-(4-octylphenyl) ethyl) propane-1,3-diol
JP2023501217A (ja) 2019-10-31 2023-01-18 イドーシア ファーマシューティカルズ リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
WO2022253077A1 (zh) 2021-05-31 2022-12-08 上海博志研新药物技术有限公司 芬戈莫德药用盐、制备方法、含其的药物组合物及应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) * 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP4079505B2 (ja) * 1998-04-28 2008-04-23 田辺三菱製薬株式会社 ２−アミノ−２−［２−（４−オクチルフェニル）エチル］プロパン−１，３−ジオールの新規な製造法
ES2237970T3 (es) * 1998-11-11 2005-08-01 Novartis Ag Produccion de 2-amino-2-(2-(4-alquil c2-20-fenil)etil)propano-1,3-dioles.
ATE216223T1 (de) * 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
IL144826A0 (en) * 1999-02-10 2002-06-30 Welfide Corp Amide compounds and pharmaceutical compositions containing the same
CN1144779C (zh) * 1999-03-11 2004-04-07 杭州中美华东制药有限公司 制备2-[2-(4-烷基苯基)-乙基]-2-氨基-丙二醇的方法以及其中制得的中间产物
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
US20030144712A1 (en) * 2001-12-20 2003-07-31 Jackson Streeter, M.D. Methods for overcoming organ transplant rejection
CA2483594C (en) * 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
ATE414508T1 (de) * 2003-04-08 2008-12-15 Novartis Pharma Gmbh Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
CN1212308C (zh) * 2003-07-24 2005-07-27 漆又毛 2－氨基－2－（2－（4－辛基苯基）乙基）－1，3－丙二醇盐酸盐的制备方法
CN1241903C (zh) * 2003-10-14 2006-02-15 马启明 制备2－对辛基苯乙基－2－氨基丙二醇的方法
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
CA2623826A1 (en) * 2005-09-30 2007-04-12 Novartis Ag Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
DK1951674T3 (da) * 2005-10-26 2012-01-02 Merck Serono Sa Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser
CN1310869C (zh) * 2005-11-22 2007-04-18 江苏吴中苏药医药开发有限责任公司 2－氨基－2－[2－(4－烷基苯基)乙基]－1,3－丙二醇的制备方法
CN100548968C (zh) * 2006-03-01 2009-10-14 徐州师范大学 一种制备2-对辛基苯乙基-2-氨基丙二醇盐酸盐的方法
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
KR101884047B1 (ko) * 2006-09-26 2018-07-31 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
JP2011525189A (ja) * 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
EP2621889B1 (en) 2010-10-01 2019-07-17 Synthon BV Process for making fingolimod hydrochloride crystals

Also Published As

Publication number Publication date
AU2009315736A1 (en) 2010-05-20
WO2010055028A2 (en) 2010-05-20
KR20130109254A (ko) 2013-10-07
WO2010055028A3 (en) 2010-07-08
CN102209705A (zh) 2011-10-05
CA2743232A1 (en) 2010-05-20
JP2014139179A (ja) 2014-07-31
KR101393994B1 (ko) 2014-05-14
RU2549899C2 (ru) 2015-05-10
EP2356090B1 (en) 2017-07-05
CA2743232C (en) 2015-12-29
ES2643161T3 (es) 2017-11-21
JP2018035160A (ja) 2018-03-08
RU2015111229A3 (pt) 2018-11-08
US8530522B2 (en) 2013-09-10
CN107233336A (zh) 2017-10-10
MX2011004962A (es) 2011-05-30
US20140051766A1 (en) 2014-02-20
US20110229501A1 (en) 2011-09-22
AU2009315736B2 (en) 2013-08-29
EP2356090A2 (en) 2011-08-17
RU2011123371A (ru) 2012-12-20
JP2016028056A (ja) 2016-02-25
CN104788325A (zh) 2015-07-22
KR20110069156A (ko) 2011-06-22
PL2356090T3 (pl) 2017-12-29
BRPI0921826A2 (pt) 2016-01-12
JP2012508216A (ja) 2012-04-05
RU2015111229A (ru) 2015-11-20

Similar Documents

Publication Publication Date Title
PT2356090T (pt) Formas cristalinas de fingolimod, hcl
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
IL212073A0 (en) Salts of fingolimod
GB0819182D0 (en) Crystalline forms
PL2262793T3 (pl) Formy krystaliczne nilotynibu HCL
ZA201105462B (en) Crystalline insulin-conjugates
IL210322A (en) A crystalline form of sitagliptin malate
GB201001075D0 (en) Crystalline forms
IL216648A0 (en) Crystalline forms of febuxostat
PL2963024T3 (pl) Krystaliczne hydraty chlorku metylotioniny - część 2
EP2365821A4 (en) CRYSTALLINE FORM OF LINACLOTIDE
GB0902406D0 (en) Crystalline polymorphic form
ZA201202405B (en) Crystallization of 4'-epidaunorubicin x hci
SI2303866T1 (sl) Kristalne oblike natrijevega rabeprazolata
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
IL200126A (en) A new process for obtaining crystalline form v of agomalatine
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
IL205451A0 (en) Crystalline forms of tigecycline hydrochloride
EP2160376A4 (en) NEW CRYSTALLINE FORMS OF ATOVAQUON
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
IL205857A0 (en) Processes for preparation of crystalline tigecyclline form ii
AU2013100530B4 (en) Crystalline forms of fingolimod HCL
HU0800755D0 (en) Novel crystalline forms
IL213288A0 (en) Crystalline forms
GB0817164D0 (en) Crystalline forms